Table 2.
Follow-up clinical assessments
| Assessments | Median (IQR) | P value (baseline –2 weeks/3/6/12/36 months) | P value (2 weeks – 3/6/12/36 months) | P value (3 – 6/12 /36 months) | P value (6 – 12/36 months) | P value (12–36 months) |
|---|---|---|---|---|---|---|
| VCSS | ||||||
| Baseline | 5.00 (4.00–7.00) | - | - | - | - | - |
| 2 weeks | 3.00 (2.00–5.00) | < 0.001* | - | - | - | - |
| 3 months | 1.00 (0.00–3.00) | < 0.001* | < 0.001* | - | - | - |
| 6 months | 1.00 (0.00 – 2.00) | < 0.001* | < 0.001* | 0.910 | - | - |
| 12 months | 1.00 (0.00 – 3.00) | < 0.001* | < 0.001* | 0.369 | 0.938 | - |
| 36 months | 0.00 (0.00 – 1.00) | < 0.001* | < 0.001* | 0.999 | 0.782 | 0.256 |
| EQ-5D TTO SG | ||||||
| Baseline | 0.686 (0.430 – 0.890) | - | - | - | - | - |
| 2 weeks | 0.854 (0.700 – 1.00) | < 0.001* | - | - | - | - |
| 3 months | 1.00 (0.854 – 1.00) | < 0.001* | 0.0015* | - | - | - |
| 6 months | 1.00 (0.854 – 1.00) | < 0.001* | 0.018* | 0.985 | - | - |
| 12 months | 1.00 (0.890 – 1.00) | < 0.001* | 0.006* | 0.999 | 0.945 | - |
| 36 months | 1.00 (0.838 – 1.00) | < 0.001* | 0.404 | 0.553 | 0.902 | 0.413 |
| AVVQ | ||||||
| Baseline | 17.1 (11.1–25.4) | - | - | - | - | - |
| 2 weeks | 11.6 (5.90–19.3) | 0.0004* | - | - | - | - |
| 3 months | 4.83 (0.00–9.78) | < 0.001* | < 0.001* | - | - | - |
| 6 months | 1.81 (0.00–6.68) | < 0.001* | < 0.001* | 0.651 | - | - |
| 12 months | 1.45 (0.00–10.7) | < 0.001* | < 0.001* | 0.653 | 1.00 | - |
| 36 months | 1.29 (0.00 – 5.39) | < 0.001* | < 0.001* | 0.579 | 0.999 | 0.999 |
| CIVIQ-14 | ||||||
| Baseline | 19.64 (12.05–28.57) | - | - | - | - | - |
| 2 weeks | 12.50 (7.14–16.96) | < 0.001* | - | - | - | - |
| 3 months | 7.14 (0.00–13.39) | < 0.001* | < 0.001* | - | - | - |
| 6 months | 5.357 (0.00–12.05) | < 0.001* | < 0.001* | 0.910 | - | - |
| 12 months | 5.357 (0.00–10.71) | < 0.001* | < 0.001* | 0.369 | 0.939 | - |
| 36 months | 7.14 (0.00–10.71) | < 0.001* | 0.0002* | 0.999 | 0.782 | 0.255 |
VCSS Venous Clinical Severity Score, EQ-5D EuroQol-5 Dimension, TTO time trade-off, AVVQ Aberdeen Varicose Vein Questionnaire, CIVIQ-14 Chronic Venous Insufficiency quality life Questionnaire-14
*Significant at p < 0.05 when compared to baseline values